The FDA has approved GlaxoSmithKline’s Trelegy Ellipta inhaler for asthma in adults, adding to its existing use in chronic obstructive pulmonary disease (COPD), stealing a march on rivals AstraZeneca ...
Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now looks set to beat a rival therapy from GlaxoSmithKline to market. Enerzair (formerly ...
Feb. 23, 2026 Scientists have created a blood test that can estimate when Alzheimer’s symptoms are likely to begin. By measuring a protein called p-tau217, the model predicts symptom onset within ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results